Relistor
(methylnaltrexone)ApprovedSmall molecule
Methylnaltrexone is used to treat constipation caused by opioid pain medications. It works by blocking opioids in the gut while allowing the pain-relieving effects to continue in the brain and body.[2] Relistor is currently approved and in use across 11 indications[4].[1]
Relistor is one of 207 small molecule programs targeting Constipation. It is currently in Approved.
11
Indications
24
Total Trials
1
Active Trials
206
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
12
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
116 competitors in Head and Neck Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Erbitux
IImclone
Phase 3
Relistor
SSalix
Approved
Beyfortus
BeiGenePhase 3
Imfinzi
AstraZenecaPhase 3
Taxotere
AAvyxa
Phase 3
Ibrance
PfizerPhase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Gilotrif
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Constipation7 trials
Show 4 more trials
MPA2 trials
Intravenous2 trials
Paralysis1 trial
Tube feeding1 trial
Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates
Withdrawn·—·Phase 3·NCT01360372
11 more indications
Cardiac Repolarization1 trial
Impaired Renal Function1 trial
Morphine1 trial
Critically Ill Patients1 trial
Postoperative Ileus1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Sep 27, 2010
RELISTOR
NDA NDA021964
Jul 19, 2016
RELISTOR
NDA NDA208271
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Relistor drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for methylnaltrexone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]